Khondrion BV   Report issue

For profit Phase 2
Founded: Nijmegen Netherlands (2012)

Organization Overview

First Clinical Trial
2015
NCT02544217
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Khondrion BV

Active Ingredients

Drugs in Phase 2 Trials (1)

kh176 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leigh Disease (Phase 1)

MELAS Syndrome (Phase 2)

Mitochondrial Diseases (Phase 2)

Mitochondrial Encephalomyopathies (Phase 2)

Mitochondrial Myopathies (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1